-
October 2018 Corporate Presentation
-
Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria
-
<i>Using Synthetic Biotic Medicines to Activate Innate and Adaptive Immunity and Drive Antitumor Immune Responses</i>
-
June 20 - 23, 2018. <br> Federation of Clinical Immunology Societies (FOCIS 2018) <br> <i>A Synthetic Biology Approach for the Treatment of Cancer and Inflammation,</i>
-
<i>June 11, 2018. <br/> Plenary Session, Precision Microbiology, annual meeting of the American Society for Microbiology (ASM Microbe 2018) <br/>An Engineered E. coli Nissle for the treatment of Phenylketonuria (PKU)</i>
-
<i> June 3, 2018. <br> Basic Science Plenary Session, <br>Digestive Disease Week® (DDW) </i>
-
The International Liver Congress™ 2018 (EASL) : April 14th , 2018 <br> <i>Tolerability and Kinetics of SYNB1020 in a Phase 1, First-in-human, Healthy Adult Volunteer Study</i>
-
<i>Metabolic Modulation of the Tumor Microenvironment using Synthetic Biotic™ Medicines</i>
-
2018 Annual meeting of the American Association for Cancer Research (AACR) April 16, 2018<br> <i>Activation of innate and adaptive immunity via combinatorial immunotherapy using Synthetic Biotic™ Medicines</i>